01-Dec-2013: Crossbeta Biosciences and AdAlta announced that they have established a collaborative relationship in which AdAlta will deploy its i-body technology to develop oligomer-specific i-bodies for therapeutic and diagnostic applications in Alzheimer’s disease using Crossbeta’s stabilized beta-amyloid oligomers. Read the full release (also in pdf format).
Watch a short presentation about Crossbeta's activities:
Learn about our Alzheimer's program in two minutes: have a look at a short presentation by our CEO Guus Scheefhals.
Stabilizing oligomers and targeting toxic oligomers is the basis for Crossbeta's oligomer drug discovery platforms which are accessible for partnering in therapeutic areas such as Alzheimer's, Parkinson's, Huntington and Diabetes Type 2.
In our Alzheimer program we have recently completed a high throughput screening campaign with 100,000 compounds resulting in the selection of 5 hit classes with >50% neutralizing effect on oligomer-induced neurotoxicity.
Stable oligomers can also be used as reference in biomarker assays.
Where to meet with us:
BIO-Europe Spring - Turin, Italy, March 10 - March 12, 2014.